Aims and Objectives: To explore lymphoma survivors' experiences on their end of treatment and follow-up care at a large urban haematology centre in Ireland.
Lymphoma survival of 10 years or more is high at 63% for NHL and 80% for HL (Cancer Research UK).
Increasing incidence and survival rates means that survivorship issues for people with lymphoma are increasingly relevant. Managing the transition phase from initial treatment to long-term survivorship is vital to long-term cancer survivorship outcomes (Hewitt, Greenfield, & Stovall, 2006) . A coordinated approach to cancer survivorship care is recommended. Survivorship care should be comprehensive and include holistic assessment and surveillance for recurrence. Moreover, it should address prevention and screening for new cancers; early detection and interventions for the physical, psychosocial and economic late effects of cancer treatment; promotion of healthy lifestyles practices; and co-ordination of care between healthcare providers (Denlinger et al., 2014; National Comprehensive Cancer Network) .
While studies reporting on the experience of cancer survivorship care predominately focus on solid tumours such as breast, prostate and lung cancer, more recent reports on haematology cancer patients' survivorship experiences highlight their many complex problems (Monterosso et al., 2017) . Specific needs include the importance of informational, emotional and support needs in the first twelve months following completion of treatment (Lobb et al., 2009) , and in particular information on fertility and sexual function (Hammond et al., 2008; Matheson et al., 2016) . Assistance with sexual relationships, body image is also major concerns for this group (Matheson et al., 2016; Parry, Morningstar, Kendall, & Coleman, 2011) , as well as dealing with medical and living expenses, emotional difficulties and problems with employment, life insurance, childcare and family (Parry et al., 2011) . In addition, other reported needs for haematology cancer survivors include managing fatigue and the need to talk to someone who has been through a similar experience (Hall et al., 2013) .
| ME TH ODOLOGY
This descriptive qualitative study aimed to explore the experiences of lymphoma survivors following completion of active treatment, with a view to understanding their experiences. Descriptive qualitative research does not aim to generate theory or interpret findings within a theoretical framework. Rather, it is an approach to providing an accurate description of events and people's response to a specific experience (Sandelowski, 2010) . The study adhered to the consolidated criteria for reporting qualitative research (COREQ) guidelines (Tong, Sainsbury, & Craig, 2007) .
| Ethical considerations
Ethical approval was granted by the hospital's research ethics committee. Access to medical records without consent was granted for the early stage of the research study in order to identify participants who fulfilled the inclusion/exclusion criteria. Written consent was obtained from each participant prior to their interview. A pseudonym was assigned to each participant. A distress protocol was developed as there was potential participant distress when discussing and reflecting on their end of treatment experiences and the effects of cancer and treatment on their lives.
| Inclusion criteria
Eligibility criteria for inclusion in the study included having a diagnosis of lymphoma which required intensive treatment, having completed treatment between 3 and 60 months prior to the study commencement, aged over 18 years, able to give consent and having fluent spoken English not requiring an interpreter.
| Recruitment and participants
The study was undertaken in a large urban university hospital specialist cancer. Potentially eligible participants were identified from the hospital's database which yielded a potential sample population of 83 adult lymphoma patients attending the cancer centre over a 5-year period from 2011 to 2015. Nineteen eligible participants were excluded for the following reasons: cognitive impairment and unable to give consent (n = 3), underage (n = 1), nonfluent English speakers requiring an interpreter (n = 1), moved away and no longer attending the centre (n = 2), surveillance only, not required treatment (n = 5), oral treatment (n = 5) and extended treatment (n = 2).
Purposive sampling was used in order to ensure that a range of age groups was represented, specifically the adolescent and young adult population (18-39 years), middle age (40-65 years) and older age (>65 years). Age is justifiable as a sampling criterion on the basis that the implications of cancer treatment and concerns in the posttreatment period can vary by lifespan age (Jones, Parry, Devine, Main, & Okuyama, 2015) . Three cases were set as the minimum number of cases required for each age category. Of those selected as suitable for the study (n = 64), all were invited by letter of invitation to participate in interview and requested to contact the first author by telephone if they wished to participate in the study.
| Data collection
All one-to-one interviews were semi-structured, audio-recorded and conducted by the first author. The interviews lasted between 18 and What this paper contributes to the greater clinical community?
• An understanding of the challenges faced by lymphoma survivors when their treatment ends.
• Highlights that some lymphoma patients may not be aware that their treatment has ended.
• Highlights the need of a dedicated end of treatment visit with a clinical nurse specialist to prepare lymphoma patients for transition to follow-up care.
• Highlights that many lymphoma patients can experience recurrent infections following treatment and need to be provided with specific health promotion advice for survivorship.
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| Data analysis
All interviews were transcribed verbatim. Data analysis was guided by thematic analysis as outlined by Braun and Clarke (2006) . This process allows for flexibility in searching for codes and themes as its six phases can be used interchangeably (Braun & Clarke, 2006) . Both authors repeatedly read each transcript interview and generated initial codes. These initial codes numbered over 60 and were given distinct labels such as "unprepared"; "persistent physical effects"; "concept of cancer"; "contact"; and "security." In phase four of the analysis process, the generated codes were discussed by both authors and five major themes (with subthemes) were agreed. The fifth phase of analysis involved a review of the themes. Therefore, the transcripts were read over again by the first author, and themes previously identified were further refined and agreed by both authors (Figure 1 ). The final phase of analysis required integration of vivid interview data in support of the identified themes.
Comprehensive field notes were taken by the first author following each interview. A reflexive diary was also kept and records were made before and after the interviews, and during data analysis.
Questions guiding reflexivity included the following: Are there any personal characteristics of mine that may have affected the study?
(age, gender and staff member); Do I hold any assumptions that I held about the participants? What do I think were possible perceptions held by participants about me? What did I expect to find during analysis that did not turn up? What did I interpret in analysis that I did not expect to find? Reflections on these questions were then discussed with the second author.
| RESULTS
The final number of participants interviewed was 14 (Table 2) . While a total of 18 participants contacted the first author, 15 expressed their agreement to participate and three declined (busy with college, examinations or travelling). One participant later declined (panic attacks), and one participant was unable to commit time to the interview process. A participant who did not fit the criteria (as he had completed treatment 8 years prior to the study) was also interviewed. He contacted the first author requesting to participate (his daughter was a study participant).
While he did not meet the study's specific inclusion criteria, the authors concluded that his request to be interviewed should be facilitated in order to uphold the principle of beneficence, that is, the potential of the qualitative interview as "therapeutic" (Birch & Miller, 2000) , and the T A B L E 1 Semi-structured Interview Guide Probe: If so, tell me about the difficulties?
Prompt:
Were they psychological, social, physical, financial?
At what point after treatment did they occur?
How do/did you cope with those difficulties?
What do you think would have been helpful in dealing with those difficulties?
Did you have an end of treatment clinic visit?
Probe: If so tell me about the visit?
Prompt
What was discussed-disease status, test results, follow up schedule, late effects, points of contact, recurrence, risks of secondary malignancies, health promotion?
What particular aspects of the visit did you find helpful?
Would you have liked further information or support at that visit?
If didn't have an end of treatment visit, would it have been helpful to you when you finished treatment?
What type of information did you receive at completion of treatment?
Probe: Was the follow up plan discussed?
Were you told about follow up schedule, late effects, points of contact, recurrence, risks of secondary malignancies, health promotion?
Would you have liked further information/support? Participants spoke about their feelings on being told they were in remission and a sense of disappointment.
It was very uneventful, I guess I thought it would be kind of a bit of a thing or I was expecting it to be Not all relationships were seen as supportive, and some described lost relationships as friends and family were unsure of how to deal with the diagnosis of cancer.
I'd have a large circle of friends but that kind of whittled down a small bit, people got scared and weren't sure how to talk to me (Ryan, 31, HL)
Many described companionships with other patients during treatment which were formed by simply chatting in the treatment
area. The open plan layout of the day unit was referred to by many as advantageous due to proximity to other patients for "sharing battle scars and battle stories" (Ryan, 31, HL). This support was not available in the post-treatment period, and only two participants shared experiences of accessing cancer support groups.
| Occupational engagement "I need to go back and get everything back to normal"
The experience of employment and occupational engagement was an important issue for participants who had previously been in employment. Returning to work was discussed in terms of getting back to normal, "treatment won't be finished until I get back working" (Owen, 51, TCL), or "a new normal" (Emily,37, HL). Some participants spoke of their inability to decide on their capacity for return to work and found the advice from healthcare professionals that "it was entirely up to you" (Emily, 37, HL) unhelpful. Returning to work for personal reasons was identified by many participants as important.
when I was working I was a very good worker, I really The impact of lingering immune deficiency on their ability to return to previous employment was an issue for some participants:
I'm not hyperaware of germs or anything but I do know that with the illness I've got that I don't need to be catching things (Martha, FL, 56) 
| Extended recovery time "the little reminders"
The majority of participants described effects from their disease and treatment which lingered long after treatment, referred to by one participant as the "the little reminders" (Emily, 37, HL), another as "damaged by chemo" (Fiona, 80, MZL) and another as "I can't have babies" (Emily, 37, HL). The most common effects experienced included fatigue, recurrent infections and weight gain. The lengthening of the time interval between visits was discussed by all participants except those with indolent lymphoma who continue three monthly visits indefinitely. In particular, this was seen as a positive sign or often referred to by participants as a "promotion" or one participant asking "will I get the marathon?" (Max, 72, DLBCL) referring to the yearly interval.
Those with indolent lymphoma, some of whom had already experienced recurrent disease, were more accepting of the risk of recurrence "it's just part of life and you get on with it" (Frank, 74, FL) and appeared to accept the limited durability of their remission and the inevitability of recurrence "I always expected it will come back sometime" (Andy, 52, FL). But they still valued the scheduled followup visit and the reassurance that "nothing has gone on in the last three months" (Frank, 74, FL).
A high value was placed on the availability of a contact number if they experienced a worrying symptom that was potentially a sign of recurrence. This direct route of contact with the hospital team was described as "like having an alarm in your house" (Ciara, 72, DLBCL) and was viewed with great significance and value by the majority of participants. Many participants described "scares" or times when they experienced night sweats or other worrying symptoms and were reviewed quickly and reassured by the hospital team.
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The scheduled follow-up hospital visit was viewed as a comprehensive surveillance for cancers and health problems. However, one unexpected finding was that continued scheduled follow-up was perceived by some participants as being "in treatment."
At follow-up, many participants did not recall any discussions on healthy lifestyle behaviours or recommended screening programmes.
Moreover, participants reported little education on the signs of lymphoma recurrence. Those who were vigilant about checking for lymphadenopathy had learned to do so by copying the technique used for the medical examination during clinic visits.
| Thoughts on a survivorship care plan
When questioned on a survivorship care plan, most participants were in favour of a written summary of treatment and follow-up, in particular information and reassurance with regards to managing ongoing symptoms, late effects and expected recovery time frame.
Some felt unprepared for managing the ongoing effects of treatment and were given no opportunity to discuss these issues. At follow-up, the majority of participants expressed the view that a review by a nurse specialist soon after they were in remission would be their choice. Most participants also indicated they wanted the care plan in written format, although some favoured it electronically, and to be made available to their general practitioner, other consultants involved in their care and carers.
| DISCUSSION
This study adds to the limited published qualitative literature describing the experiences of lymphoma survivors. For some, the transition phase when treatment ended was uneventful, but for others, it was abrupt and traumatic and they felt unprepared. This was felt most strongly by those who had undergone intensive primary chemotherapy and were transferred for scheduled follow-up once remission was achieved. These participants missed monitoring by the treatment team. These findings are also reported by other lymphoma survivors who describe a sense of abandonment and feeling unsupported when interaction with the treating team is less frequent (Monterosso et al., 2017; Parry et al., 2011) .
This finding suggests the need for healthcare providers to communicate that the time of transition from active treatment can be challenging and provide a point of contact and appropriate referral to support services. Younger lymphoma survivors in particular may be more likely to report unmet needs in dealing with emotional and family problems (Parry, Lomax, Morningstar, & Fairclough, 2012) and having higher levels of cancer-specific distress (Brant et al., 2011; Jones et al., 2015) . In addition, young adults who received combined treatment modalities were found to have substantial symptoms at 6-month time point following treatment (Muffly et al., 2016) .
Positive life changes and more meaningful relationships were also described by participants. This is consistent with previous research in the area of post-traumatic growth, which relates to benefits in life perspectives, interpersonal relationships and self-perception following an event, both generally (Calhoun & Tedeschi, 2001 ) and specifically with NHL survivors (Bellizzi, Miller, Arora, & Rowland, 2007) . However, this fades over time as the experience integrates into daily life (Cormio et al., 2010) .
Participants also described longer term physical effects such as recurrent infections and fatigue. These findings reflect those reported by long-term cancer survivors (n = 3138) in the United
States, and survivors' greatest need was for information on longterm treatment side effects (Playdon et al., 2016) .
The prolonged effect on the immune system may be accounted for by immune deficiency which is inherent in haematological malignancies and compounded by the effect of combined modalities of chemotherapy, radiotherapy, immunosuppressive therapy and immunotherapy treatment on the immune system.
Additionally, the majority of participants, some post-treatment up to 5 years, described ongoing fatigue. This is reported in other studies of haematology cancer survivors (Korszun et al., 2014; Hall et al., 2013 ) and non-haematological cancer survivors (Wu & Harden, 2015) .
Moreover, even with the return of precancer muscle characteristics and function, HL survivors' self-reported fatigue remains a burden (de Lima et al., 2018) . Physical activity has been shown to result in a moderate beneficial effect on lymphoma patients' fatigue, but engagement with the physical activity must be consistent to achieve this result (Husson, Oerlemans, Mols, Schep, & Van De Poll-Franse, 2015) .
Issues with weight management, specifically weight gain, were an unexpected finding in this study. Weight gain post-diagnosis is well described in breast cancer survivors (Vance, Mourtzakis, McCargar, & Hanning, 2011) , but little is known about this experience among lymphoma survivors. A higher than expected weight gain in adult lymphoma patients for up to 18 months' post-treatment has been found, but the mechanism for weight gain is not fully understood (Lynce, Pehlivanova, Catlett, & Malkovska, 2012) . It has also been reported that adverse prolonged body composition changes can occur with increased weight and decreased muscle mass in male NHL survivors following treatment with chemotherapy (Xiao et al., 2016) . Referral of lymphoma patients to the clinical nutritionist is mainly as a reaction to weight loss at diagnosis or as a result of intensive treatments, such as allogeneic transplant. Our findings would suggest the need for increased awareness by healthcare professionals of the need for lifestyle interventions and weight management advice and referral for lymphoma patients.
Patient concerns, challenges, barriers and facilitating factors regarding returning to work after treatment are highlighted in this study. Employer support and flexibility were the main factor which aided return to work, reflecting findings reported elsewhere (McGrath, Hartigan, Holewa, & Skarparis, 2012) . The main barriers to return to previous employment were noted to be lingering immune deficiency and fatigue. Healthcare professionals should consider the impact of treatment on patients' ability to return to work and support patients accordingly by appropriate referral.
Overall, participants valued scheduled follow-up and, in particular, valued results of blood tests for detecting recurrence. This is despite low numbers of patients experiencing relapse being detected at scheduled follow-up with most having clinical signs and symptoms (Thompson et al., 2014) . The purpose of structured follow-up and review includes monitoring for disease relapse, late effects of treatment and development of second malignancies and health promotion advice. However, many participants did not recall any discussions on healthy lifestyle behaviours or relevant recommended cancer screening programmes for age and gender, and some overlooked regular screening programmes. It has been reported elsewhere that, during follow-up consultations, doctors tend not to be organised and systematic in their approach to health promotion with lymphoma patients and it is patients that highlight their engagement with healthy behaviours without prompting (Franco et al., 2017) .
Similar to findings by Marbach and Griffie (2011) , the majority of participants were in favour of a written summary of treatment and survivorship care plan, either in paper or electronic form, delivered by a nurse specialist at a dedicated visit and made available to others involved in their care. Cancer nurses have been identified as potential providers of survivorship care including addressing issues of concern and providing education, support and co-ordination (Marbach & Griffie, 2011) and developing survivorship care recommendations into survivorship care plans (Taylor & Monterosso, 2015) .
| LIMITATIONS
The sample size was small and restricted to one haematology centre.
Therefore, generalisability to all lymphoma survivors is limited.
| CONCLUSIONS
The findings suggest that the transition period for lymphoma survivors following active treatment can be challenging, and they have ongoing needs. This finding is similar to the experiences of patients with non-haematological cancers. However, this cohort of patients clearly require more preparation for the end of active treatment because some may not even be aware that treatment has finished.
Education and promotion of healthy lifestyles, monitoring for late effects and second cancers, are also vital for lymphoma survivors.
Moreover, the findings highlight the need for healthcare professionals to ensure the provision of a point of contact and appropriate referral to support services such as counselling, clinical nutrition and physiotherapy at the end of active treatment. The importance of coordination of information between acute and primary healthcare providers in monitoring for and management of late effects of treatment and promoting the uptake of recommended programmes for cancer surveillance is also highlighted.
| RELEVAN CE TO CLINICAL PRACTICE
This study highlights the need for a dedicated end of treatment visit with a clinical nurse specialist to confirm the completion of active treatment with lymphoma patients. This end of treatment visit should also outline the purpose of post-treatment follow-up and the importance of patients identifying the signs of cancer recurrence. Scheduled follow-up could then offer an opportunity to continue ongoing needs assessment, appropriate referral and a focus on health promotion. Further research is required to determine the feasibility of survivorship care plans to an already under-resourced specialist nursing service in Ireland and if any education needs exist for haematology nurse specialists in the area of survivorship care.
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